[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epstein-barr-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epstein-barr-virus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,145,171,199,227,255,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629767","phase-1-a-study-of-an-epstein-barr-virus-ebv-candidate-vaccine-mrna-1189-in-healthy-adults-18-to-30-years-of-age-100629767",false,"NCT07478952","A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","A Phase 1, Randomized, Open-label Study to Evaluate Safety, Reactogenicity, and Immunogenicity of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, Following Intradermal and Intramuscular Delivery in Healthy Adults 18 to 30 Years of Age","Inclusion Criteria:\n\n* Healthy as determined by medical evaluation including medical history and physical examination.\n* Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast\u002Fchest feeding.\n\nExclusion Criteria:\n\n* Have undergone surgical procedures within 7 days prior to Day 1 or Day 57 or are scheduled to undergo a surgical procedure within 28 days after study intervention administration.\n* Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infectious disease.\n* Received corticosteroids at ≥10 milligrams per day (mg\u002Fday) of prednisone or equivalent for \\>14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study.\n* Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses, within 180 days prior to Day 1 or plans to do so during the study.\n* Received or plans to receive any nonstudy vaccine from 28 days prior to first dose\u002FDay 1 up to 28 days after the second dose\u002FDay 57.\n* History of myocarditis, pericarditis, or myopericarditis prior to Day 1.\n* Has previously received an investigational EBV vaccine.\n\nNote: Other inclusion and exclusion criteria may apply.",true,"ALL","18 Years","30 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.",[28],"Epstein-Barr Virus",[30],"Epstein-Barr Virus (EBV)","RECRUITING","2026-03-20",{"date":34,"type":35},"2026-03-24","ACTUAL",{"date":37,"type":35},"2026-03-17",{"date":39,"type":22},"2027-05-15",{"name":41,"class":42},"ModernaTX, Inc.","INDUSTRY",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":54,"type":22},10000,"OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":136,"type":35},"2026-01-22",{"date":138,"type":35},"2025-12-18",{"date":140,"type":22},"2027-09-30",{"name":142,"class":143},"Institut Pasteur du Cambodge","OTHER",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":144},"100587323","phase-1-r-mvst-cells-for-treatment-of-viral-infections-in-children-and-young-adults-100587323","NCT06926894","R-MVST Cells for Treatment of Viral Infections in Children and Young Adults","Single Center Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells for Immunodeficient Children and Young Adults","Inclusion Criteria:\n\n* Children and young adults (3 months to \\\u003C26 years) of all ethnic groups will be eligible for the treatment\n* Patients with history of HCT or SOT who demonstrate evidence of viral reactivation and\u002For infection manifesting as end-organ or systemic disease due to one or more of the following viruses: EBV, CMV, ADV or BK virus and suboptimal response to the standard of care therapy.\n* Recurrent or Multiple Viral Infection. RVI defined as occurrence of more than one episode of reactivation that required intervention or symptomatic disease in recipient of allogeneic HCT that required standard of care treatment. MVI defined as more than one virus reactivating (defined by PCR positivity) or causing symptomatic systemic or end-organ disease. At least one of those viral reactivations required standard of care intervention. No standard of care therapy is defined for ADV and BK. Patients with multiple infections\u002Freactivations will be eligible as long as at least one of those viral infections meet the criterium of \"refractory\".\n\nExclusion Criteria:\n\n* Patients with other uncontrolled infections, except for CMV, EBV, ADV or BK. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to the day of infusion. For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to R-MVST infusion. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n* Patients who receive corticosteroids at ≥ 0.5mg\u002Fkg prednisone or equivalent.\n* Patients who received anti-thymocyte globulin (ATG, Alemtuzumab (Campath), or other T-Cell immunosuppressive monoclonal antibodies in the last 28 days.\n* Patients who received methotrexate, or other antimetabolite-type immunosuppressants that are toxic to proliferating T cells in the last 7 days.\n* Patients who received extracorporeal photopheresis within the last 28 days.\n* Patients who received checkpoint inhibitor agents (e.g., nivolumab, pembrolizumab, ipilimumab) within 3 drug half-lives of the most recent dose to the infusion of R-MVST.\n* Received donor lymphocyte infusion in last 28 days.\n* Evidence of GVHD ≥ grade 2\n* Evidence of biopsy-proven acute rejection in SOT recipients\n* Active and uncontrolled relapse of malignancy\n* Patients who are pregnant, or breastfeeding.\n* Female of childbearing potential, or male with a female partner of childbearing potential, unwilling to use a highly effective method of contraception.\n* Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Patients who have received investigational (IND) product within 14 days of infusion of the the R-MVST cells.\n* Unable or unwilling to receive infusions at Morgan Stanley Children's Hospital.","3 Months","26 Years",{"count":155,"type":22},18,[25],"The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and\u002For symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion.\n\nSecondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.",[28,159,92,160,161],"Cytomegalovirus Infections","BK Virus Infection","Immune Deficiency","2025-07-29",{"date":164,"type":35},"2025-07-31",{"date":166,"type":35},"2025-04-20",{"date":168,"type":22},"2030-12",{"name":170,"class":143},"Columbia University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":144},"100582985","comparison-and-strategy-optimization-of-plasma-ebv-dna-and-p85-ab-with-vcaebna1-iga-for-screening-nasopharyngeal-carcinoma-in-high-risk-areas-100582985","NCT06870435","Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA\u002FEBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas","Comparison and Strategy Optimization of Plasma Epstein-Barr Virus (EBV) DNA and BNLF2b Total Antibodies (P85-Ab) with VCA-IgA and EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas","Inclusion Criteria:\n\n* Voluntarily signed informed consent.\n* Age between 30 and 69 years at the time of screening.\n* Residents of Guangdong Province or Guangxi Province.\n* Able to cooperate with long-term follow-up.\n\nExclusion Criteria:\n\n* Severe medical comorbidities, significant organ (heart, lung, liver, kidney) dysfunction, or psychiatric disorders.\n* Severe autoimmune diseases or immunodeficiency.\n* History of or current malignant tumors.\n* Inability to cooperate with the study due to psychological, social, familial, or geographical reasons.","69 Years",{"count":180,"type":22},68649,[182],"NA","This study is a prospective, self-controlled, multicenter clinical trial. All participants will be tested for Epstein-Barr virus (EBV) associated biomarkers, including the two-antibody method (VCA-IgA and EBNA1-IgA), BNLF2b total antibodies (P85-Ab), and plasma EBV DNA. Furthermore, novel screening biomarkers, such as next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, will be explored.\n\nFirst, it aims to investigate whether plasma EBV DNA testing or the P85-Ab testing can achieve higher sensitivity than the current standard two-antibody method testing while maintaining specificity in NPC screening, thereby identifying the optimal initial NPC screening strategy. Based on the determined optimal initial screening strategy, the study will validate the proposed two-step method (subjects first undergo two-antibody method testing and P85-Ab testing; those positive for either one biomarker above proceed to plasma EBV DNA testing; subjects positive in both steps are defined as high-risk and receive endoscopic examinations with or without biopsy) compared with the single-step method (subjects simultaneously undergo two-antibody method testing, P85-Ab testing, and plasma EBV DNA testing; subjects with any positive biomarker undergo endoscopic examinations with or without biopsy) and each single screening testing. The aim is to determine whether two-step method can further improve the positive predictive value (PPV) while maintaining non-inferior sensitivity, thereby enhancing screening efficiency, reducing the rate of invasive procedures (such as endoscopic biopsies), and lowering medical costs and insurance burdens.",[185,186,97],"Nasopharyngeal Carcinoma (NPC)","Screening",[185,186,97,188,189],"EBV DNA","EBV antibody","2025-03-06",{"date":192,"type":35},"2025-03-11",{"date":194,"type":35},"2025-01-24",{"date":196,"type":22},"2035-12-31",{"name":198,"class":143},"Ming-Yuan Chen",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":207,"maxAge":19,"enrollmentInfo":208,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100553039","exploratory-study-of-ebv-dna-titre-clearance-whilst-on-proton-beam-therapy-100553039","NCT06480903","Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy","Exploratory Study of Plasma Epstein Barr Virus (EBV) DNA Clearance During Proton Beam Therapy (PBT) for Nasopharyngeal Carcinoma (NPC)","ClearED","Inclusion Criteria:\n\n* Children and young adults (8-30 years old)\n* Pathologically confirmed EBV-positive nasopharyngeal carcinoma\n* Stage I-IVA (AJCC 8th Edition)\n* Planned to commence curative-intent radiation therapy\n\nExclusion Criteria:\n\n* Recurrent NPC\n* Concurrent or previously treated EBV-associated malignancy\n* Prior radiation therapy\n* Contraindications to MRI\n* General anaesthetic requirement for MRI","8 Years",{"count":209,"type":22},10,"How does plasma Epstein-Barr Virus (EBV) DNA level change during definitive radiation therapy for nasopharyngeal carcinoma (NPC) in the teenage and young adult cohort and does it correlate with outcomes?",[212,213,214,28],"Nasopharyngeal Carcinoma","Head and Neck Cancer","Nasopharyngeal Cancer",[216],"Nasopharyngeal, cancer, proton beam, epstein-barr virus","NOT_YET_RECRUITING","2024-06-25",{"date":220,"type":35},"2024-06-28",{"date":222,"type":22},"2024-08-30",{"date":224,"type":22},"2026-08-30",{"name":226,"class":143},"The Christie NHS Foundation Trust",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":144},"100548881","graves-disease-induced-by-epstein-barr-virus-lytic-reactivation-100548881","NCT06426758","Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation","The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation","Inclusion Criteria:\n\n* The clinical evaluation included patient history, physical examination, and thyroid ultrasonography. Laboratory and diagnostic testing included determination of serum levels of free thyroxine (FT4), T3 ( FT3), thyrotropin (TSH), TPOAb, TGAb, and serum levels of thyrotropin receptor antibody (TRAb).\n\nExclusion Criteria:\n\n* Patients with subacute thyroiditis, hyperfunctioning thyroid nodules, iodine hyperthyroidism, drug-induced hyperthyroidism, or other causes of hyperthyroidism were also excluded. The exclusion criteria for both patients with GD included diabetes, infectious diseases, other chronic diseases, and cancer.","70 Years",{"count":236,"type":22},300,"Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood. We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In order to confirm lytic reactivation of EBV, the number of EBV DNA copies，mRNA and protein expression of immediate-early, early and late lytic EBV genes，EBV +TRAb+cells will be tested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated.",[239,240,28],"Graves Disease","Graves' Disease in Remission",[239,242,243,244,245],"Relapse of hyperthyroidism","Epstein-Barr virus","Lytic reactivation","Morbidity","2024-05-19",{"date":248,"type":35},"2024-05-23",{"date":250,"type":22},"2024-05-30",{"date":252,"type":22},"2027-09-01",{"name":254,"class":143},"Xiao-Ming Mao",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":144},"100526188","segmental-resection-combined-with-dep-regimen-for-ebv-hlh-patients-with-intestinal-involvement-100526188","NCT06131489","Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement","Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* EBV-DNA in the peripheral blood \\> 1000 copies\u002Fml or EBV-encoded small RNA (EBER) detected in tissues;\n* Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;\n* Age \\>18 years old, gender is not limited;\n* Estimated survival time \\> 1 month;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Active infections (viral, bacterial, fungal or parasitic);\n* Diagosed with malignant tumos within 5 years；\n* Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;\n* Heart function above grade II (NYHA);\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN;\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease;\n* Pregnancy or lactating Women;\n* Allergic to pegylated liposomal doxorubicin and etoposide;\n* HIV antibody positivity;\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);\n* Participate in other clinical research at the same time;\n* The researchers considered that patients are not suitable for the study.",{"count":263,"type":22},20,"EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.",[266,28,267],"Hemophagocytic Lymphohistiocytosis","Bowel Resection","2023-11-09",{"date":270,"type":35},"2023-11-14",{"date":272,"type":22},"2023-12-01",{"date":274,"type":22},"2027-01-01",{"name":276,"class":143},"Beijing Friendship Hospital",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":144},"100498857","phase-3-l-dep-regimen-combined-with-pd-1-antibody-as-induction-therapy-for-epstein-barr-virus-positive-la-hlh-100498857","NCT05775705","L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","The Efficacy and Safety of L-DEP Regimen Combined With PD-1 Antibody an Induction Therapy for Epstein-Barr Virus (EBV)-Positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.\n* EBV-DNA in peripheral blood \\> 1000 copies\u002Fml or EBER detected in tissue specimens.\n* Age 18\\~65，gender is not limited.\n* Estimated survival time ≥ 1 month.\n* Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \\>250.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Heart function above grade II (NYHA).\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN.\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease.\n* Pregnancy or lactating Women.\n* Allergic to pegylated liposomal doxorubicin，etoposide，or PD-1 antibody.\n* Thyroid dysfunction.\n* HIV antibody positivity.\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable).\n* Participate in other clinical research at the same time.\n* The researchers considered that patients are not suitable for the study.","65 Years",{"count":286,"type":22},25,[288],"PHASE3","The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.",[291,266,28,292],"PD-1 Antibody","Lymphoma","2023-03-08",{"date":295,"type":35},"2023-03-20",{"date":297,"type":22},"2023-08-01",{"date":299,"type":22},"2026-10-01",{"name":276,"class":143}]